Long Non-Coding RNAs: Crucial Regulators in Alzheimer's Disease Pathogenesis and Prospects for Precision Medicine

Overview

Journal Mol Neurobiol

Date 2025 Feb 5

PMID 39907902

Authors

Chenbo Yang

Yiwei Li

Chao Chen

Zexin Sun

Enjie Liu

Na Wei

Xiaonan Liu

Jiao Shu

Na Zhao

Miaomiao Sun

Affiliations

Soon will be listed here.

Abstract

Long non-coding RNAs (LncRNAs) have emerged as pivotal regulators in the pathogenesis of Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. With the capacity to modulate gene expression at various levels, LncRNAs are implicated in multiple pathological mechanisms of AD, including amyloid-beta (Aβ) accumulation, tau protein phosphorylation, neuroinflammation, and neuronal apoptosis. Recent studies have highlighted the potential of LncRNAs as diagnostic biomarkers and therapeutic targets due to their differential expression patterns in AD patients. This review synthesizes current knowledge on the role of LncRNAs in AD, focusing on their involvement in key molecular pathways and their promise as indicators for early diagnosis and prognosis. We discuss the regulatory networks of LncRNAs in the context of AD, their interaction with miRNAs, and the implications for developing novel therapeutic strategies. Despite the complexity and variability in LncRNA function, the prospect of harnessing these molecules for precision medicine in AD is gaining momentum. The translational potential of LncRNA-based interventions offers a new frontier in the quest for effective treatments and a deeper understanding of the molecular underpinnings of AD.

References

Janoutova J, Kovalova M, Machaczka O, Ambroz P, Zatloukalova A, Nemcek K . Risk Factors for Alzheimer's Disease: An Epidemiological Study. Curr Alzheimer Res. 2021; 18(5):372-379. DOI: 10.2174/1567205018666210820124135. View

Yu H, Wu J . Amyloid-β: A double agent in Alzheimer's disease?. Biomed Pharmacother. 2021; 139:111575. DOI: 10.1016/j.biopha.2021.111575. View

Tatulian S . Challenges and hopes for Alzheimer's disease. Drug Discov Today. 2022; 27(4):1027-1043. DOI: 10.1016/j.drudis.2022.01.016. View

Ju Y, Tam K . Pathological mechanisms and therapeutic strategies for Alzheimer's disease. Neural Regen Res. 2021; 17(3):543-549. PMC: 8504384. DOI: 10.4103/1673-5374.320970. View

Kopp F, Mendell J . Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell. 2018; 172(3):393-407. PMC: 5978744. DOI: 10.1016/j.cell.2018.01.011. View

Yang Z, Jiang S, Shang J, Jiang Y, Dai Y, Xu B . LncRNA: Shedding light on mechanisms and opportunities in fibrosis and aging. Ageing Res Rev. 2019; 52:17-31. DOI: 10.1016/j.arr.2019.04.001. View

Busscher D, Boon R, Juni R . The multifaceted actions of the lncRNA H19 in cardiovascular biology and diseases. Clin Sci (Lond). 2022; 136(15):1157-1178. PMC: 9366862. DOI: 10.1042/CS20210994. View

Graff-Radford J, Yong K, Apostolova L, Bouwman F, Carrillo M, Dickerson B . New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurol. 2021; 20(3):222-234. PMC: 8056394. DOI: 10.1016/S1474-4422(20)30440-3. View

Lane C, Hardy J, Schott J . Alzheimer's disease. Eur J Neurol. 2017; 25(1):59-70. DOI: 10.1111/ene.13439. View

10.

Zaratiegui M, Irvine D, Martienssen R . Noncoding RNAs and gene silencing. Cell. 2007; 128(4):763-76. DOI: 10.1016/j.cell.2007.02.016. View

11.

Uszczynska-Ratajczak B, Lagarde J, Frankish A, Guigo R, Johnson R . Towards a complete map of the human long non-coding RNA transcriptome. Nat Rev Genet. 2018; 19(9):535-548. PMC: 6451964. DOI: 10.1038/s41576-018-0017-y. View

12.

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

13.

Twarowski B, Herbet M . Inflammatory Processes in Alzheimer's Disease-Pathomechanism, Diagnosis and Treatment: A Review. Int J Mol Sci. 2023; 24(7). PMC: 10095343. DOI: 10.3390/ijms24076518. View

14.

Lee H, Jeong M, Jang S . Molecular Characteristics of Amyloid Precursor Protein (APP) and Its Effects in Cancer. Int J Mol Sci. 2021; 22(9). PMC: 8125876. DOI: 10.3390/ijms22094999. View

15.

Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M . Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019; 14:5541-5554. PMC: 6650620. DOI: 10.2147/IJN.S200490. View

16.

Dong L, Zhang Y, Bao H, Liu Y, Zhang G, An F . LncRNA NEAT1 promotes Alzheimer's disease by down regulating micro-27a-3p. Am J Transl Res. 2021; 13(8):8885-8896. PMC: 8430163. View

17.

Huang Z, Zhao J, Wang W, Zhou J, Zhang J . Depletion of LncRNA NEAT1 Rescues Mitochondrial Dysfunction Through NEDD4L-Dependent PINK1 Degradation in Animal Models of Alzheimer's Disease. Front Cell Neurosci. 2020; 14:28. PMC: 7043103. DOI: 10.3389/fncel.2020.00028. View

18.

Gao S, Fan C, Wang Y, Yang W, Jiang H . LncRNA ENST00000440246.1 Promotes Alzheimer's Disease Progression by Targeting PP2A. Biochem Genet. 2023; 62(3):2100-2116. DOI: 10.1007/s10528-023-10552-0. View

19.

Liu Q, Ling Z, Zhang J, Yu H, Wang Y, Xue Y . lncRNA MIR600HG Knockdown Alleviates Cognitive Impairment in Alzheimer's Disease Through NEDD4L Mediated PINK1 Degradation. J Alzheimers Dis. 2021; 85(4):1783-1794. DOI: 10.3233/JAD-215194. View

20.

Yan X, Liu H, Hong Y, Meng T, Du J, Chang C . lncRNA XIST induces Aβ accumulation and neuroinflammation by the epigenetic repression of NEP in Alzheimer's disease. J Neurogenet. 2022; 36(1):11-20. DOI: 10.1080/01677063.2022.2028784. View